The full content of Annals is available to subscribers

Subscribe/Learn More  >
ACP Journal Club |

Cangrelor reduced ischemic PCI complications more than clopidogrel without increasing severe bleeding

Ann Intern Med. 2013;158(12):JC5. doi:10.7326/0003-4819-158-12-201306180-02005
Text Size: A A A





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
CHAMPION-PHOENIX: Not so champion.
Posted on June 27, 2013
Anil Pandit, MD
Division of Cardiovascular Diseases, Mayo Clinic, Arizona
Conflict of Interest: None Declared

Dear Editor:I read, “Cangrelor reduced ischemic PCI complications more than clopidogrel with increasing severe bleeding,” with a great interest. The authors have done a remarkable job summarizing the findings of the study. However, the commentary misses several important points regarding CHAMPION-PHOENIX trial:

1. There was no difference in Q wave MI between study groups (OR 0.61, 95% CI = 0.29-1.29, P = 0.19), which carries clinical significance rather than biomarkers positive myocardial infarction.

2. Loading dose of clopidogrel was either 300 or 600 mg at the discrention of treating physician. Obiviously, 300 mg is inferior to 600 mg loading dose of clopidogrel leading to suboptimal efficacy in those receiving 300 mg. About one third of patients in the trial were treated with 300 mg loading dose of clopidogrel.

3. Although risk of stent thrombosis and myocardial infarction was lower in cangrelor group, these findings did not translate into lower risk of ischemia driven revascularization (OR 0.74, 95% CI = 0.45-1.20) and death (OR 1.0, 95% CI = 0.52-1.92).

4. Median time from admission to PCI in the trial was 4.4 hours. But, by the definition of biomarkers positive MI requires two samples drawn at least 6 hours apart. It is unlikely that patients in the trial had two sets of biomarkers before PCI.5. Stratifying data based on biomarkers positive and negative would have yielded better information from the trial, which was not performed.In summary, although cangrelor use was associated with reduction in primary end point compared with clopidogrel. The benefit was mainly driven by reduced risk of stent thrombosis and myocardial infarction. The reduction in myocardial infarction and stent thrombosis did not translate into reduction of ischemia driven revascularization and death. Based on these points, the role of cangrelor in PCI is questionable.

Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.